AbbVie (NYSE:ABBV – Get Free Report) had its price target raised by equities research analysts at Barclays from $325.00 to $335.00 in a research note issued to investors on Monday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Barclays‘s target price would indicate a potential upside of 12.33% from the company’s previous close.
ABBV has been the subject of a number of other research reports. UBS Group lifted their price target on AbbVie from $275.00 to $295.00 and gave the company a “neutral” rating in a research note on Monday, November 2nd. Wells Fargo & Company increased their price objective on AbbVie from $300.00 to $340.00 and gave the stock an “overweight” rating in a research note on Monday, November 2nd. Scotiabank raised their target price on AbbVie from $280.00 to $320.00 and gave the company an “outperform” rating in a report on Tuesday, October 6th. Guggenheim lifted their target price on AbbVie from $288.00 to $322.00 and gave the company a “buy” rating in a research report on Monday, November 2nd. Finally, Piper Sandler lifted their target price on AbbVie from $298.00 to $303.00 and gave the company an “overweight” rating in a research report on Thursday, August 20th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $297.85.
Read Our Latest Report on ABBV
AbbVie Price Performance
Shares of NYSE ABBV traded up $3.19 during mid-day trading on Monday, reaching $298.22. 493,930 shares of the company’s stock traded hands, compared to its average volume of 6,270,022. The business has a 50-day simple moving average of $275.51 and a 200 day simple moving average of $240.91. The stock has a market cap of $527.14 billion, a P/E ratio of 51.41, a PEG ratio of 1.34 and a beta of 0.20. AbbVie has a 1-year low of $190.75 and a 1-year high of $302.93.
AbbVie (NYSE:ABBV – Get Free Report) last posted its earnings results on Friday, October 30th. The company reported $3.82 earnings per share for the quarter, topping analysts’ consensus estimates of $3.73 by $0.09. AbbVie had a net margin of 15.67% and a negative return on equity of 450.55%. The company had revenue of $17.40 billion for the quarter, compared to analyst estimates of $17.32 billion. During the same quarter in the prior year, the business posted $1.86 EPS. The firm’s revenue was up 10.3% compared to the same quarter last year. Equities research analysts anticipate that AbbVie will post 13.98 earnings per share for the current fiscal year.
Insiders Place Their Bets
In related news, EVP Jeffrey Stewart sold 40,619 shares of the business’s stock in a transaction dated Monday, November 9th. The shares were sold at an average price of $293.60, for a total transaction of $11,925,738.40. Following the transaction, the executive vice president directly owned 83,171 shares in the company, valued at approximately $24,419,005.60. The trade was a 32.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.06% of the company’s stock.
Institutional Investors Weigh In On AbbVie
Several institutional investors and hedge funds have recently added to or reduced their stakes in ABBV. Verus Financial Partners Inc. raised its position in AbbVie by 1.7% in the third quarter. Verus Financial Partners Inc. now owns 2,048 shares of the company’s stock valued at $536,000 after purchasing an additional 35 shares during the period. Evergreen Private Wealth LLC boosted its position in shares of AbbVie by 3.3% during the third quarter. Evergreen Private Wealth LLC now owns 1,090 shares of the company’s stock worth $285,000 after buying an additional 35 shares during the period. Lifelong Wealth Advisors Inc. boosted its position in shares of AbbVie by 2.1% during the third quarter. Lifelong Wealth Advisors Inc. now owns 1,755 shares of the company’s stock worth $459,000 after buying an additional 36 shares during the period. IMG Wealth Management Inc. boosted its position in shares of AbbVie by 22.8% during the third quarter. IMG Wealth Management Inc. now owns 194 shares of the company’s stock worth $51,000 after buying an additional 36 shares during the period. Finally, Foundry Financial Group Inc. grew its stake in shares of AbbVie by 4.6% in the third quarter. Foundry Financial Group Inc. now owns 839 shares of the company’s stock valued at $219,000 after buying an additional 37 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.
AbbVie Company Profile
AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.
Featured Articles
- Five stocks we like better than AbbVie
- Sandisk’s Sell-Off May Be Losing Steam, But the Biggest Risk Still Looms
- Meta’s Access to Capital Remains Strong, But Borrowing Is Becoming More Expensive
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
